PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 22822061-1 2012 TLR9 is a receptor for sensing bacterial DNA/CpG-containing oligonucleotides (CpG ODN). Oligonucleotides 60-76 toll like receptor 9 Homo sapiens 0-4 22617774-3 2012 Our previous study showed that TLR9 response to CpG oligonucleotide (ODN) in 95D human lung cancer cells could enhance their growth and invasive potential in vitro and in vivo. Oligonucleotides 52-67 toll like receptor 9 Homo sapiens 31-35 22934281-1 2012 CpG oligonucleotides stimulate via TLR9 and enhance anti-tumor immunity, an effect attributed to the activation of NK and CD8(+) T cells. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 35-39 22613717-0 2012 Heterozygous carriage of a dysfunctional Toll-like receptor 9 allele affects CpG oligonucleotide responses in B cells. Oligonucleotides 81-96 toll like receptor 9 Homo sapiens 41-61 22675199-4 2012 pDC type I IFN responses to TFAM and CpG-containing oligonucleotide, type A, DNA indicated their engagement with receptors for advanced glycation end products and TLR9, respectively, and were dependent upon endosomal processing and PI3K, ERK, and NF-kappaB signaling. Oligonucleotides 52-67 toll like receptor 9 Homo sapiens 163-167 22086297-4 2012 To neutralize such danger, we have pioneered the development of potent TLR9 pathway antagonists, inhibitory oligonucleotides (INH-ODNs), which work in a sequence-specific manner. Oligonucleotides 108-124 toll like receptor 9 Homo sapiens 71-75 22708497-2 2012 Oligonucleotides expressing immunostimulatory CpG motifs (CpG ODN) stimulate cells that express Toll-like receptor 9 to initiate an inflammatory response. Oligonucleotides 0-16 toll like receptor 9 Homo sapiens 96-116 21812536-1 2012 CpG oligonucleotide 7909 (CpG 7909, PF-03512676), a synthetic 24mer single stranded agonist of TLR9 expressed by B cells and plasmacytoid dendritic cells, is immunomodulatory and can cause activation-induced death of chronic lymphocytic leukemia (CLL) cells. Oligonucleotides 4-19 toll like receptor 9 Homo sapiens 95-99 20843814-2 2010 For example, TLR9 is activated by microbial DNA and also by short therapeutic CpG-containing oligonucleotides (CpG-ODN). Oligonucleotides 93-109 toll like receptor 9 Homo sapiens 13-17 23238459-7 2012 CONCLUSIONS: The available results gathered from preclinical and clinical studies suggest that TLR9-targeted therapy of oligonucleotides can stimulate both innate and adaptive immunity. Oligonucleotides 120-136 toll like receptor 9 Homo sapiens 95-99 21890455-2 2011 We previously showed that the novel Toll-like receptor 9 (TLR9) agonist immunomodulatory oligonucleotide (IMO) has a strong in vivo activity in colorectal cancer models by interfering with EGFR-related signaling and synergizing with the anti-EGFR monoclonal antibody cetuximab. Oligonucleotides 89-104 toll like receptor 9 Homo sapiens 36-56 21890455-2 2011 We previously showed that the novel Toll-like receptor 9 (TLR9) agonist immunomodulatory oligonucleotide (IMO) has a strong in vivo activity in colorectal cancer models by interfering with EGFR-related signaling and synergizing with the anti-EGFR monoclonal antibody cetuximab. Oligonucleotides 89-104 toll like receptor 9 Homo sapiens 58-62 21376154-4 2011 We and others have created inhibitory oligonucleotides (INH-ODN) that are capable of sequence-dependent inhibition of TLR9-induced activation in both human and mouse cells. Oligonucleotides 38-54 toll like receptor 9 Homo sapiens 118-122 21392514-5 2011 Following blockade of TLR9 receptors with oligonucleotide-inhibitor or chloroquine in the bystander cells these effects - except of activation of NORs - on exposure to ecDNA(R) disappeared, with no bystander response thus observed. Oligonucleotides 42-57 toll like receptor 9 Homo sapiens 22-26 22866107-7 2011 Selective TLR-9 agonism with CpG oligonucleotides led to a significant increase in MMP-13 gene expression after 12 h of incubation in LS174 cells and after 12 and 24 h in SW620 cells, but not when using GpC oligonucleotides as a control substance. Oligonucleotides 33-49 toll like receptor 9 Homo sapiens 10-15 21483736-1 2011 Toll-like receptor 9 (TLR9) activates the innate immune system in response to oligonucleotides rich in CpG whereas DNA lacking CpG could inhibit its activation. Oligonucleotides 78-94 toll like receptor 9 Homo sapiens 22-26 21393636-0 2011 Optimal oligonucleotide sequences for TLR9 inhibitory activity in human cells: lack of correlation with TLR9 binding. Oligonucleotides 8-23 toll like receptor 9 Homo sapiens 38-42 21978158-5 2011 We found that disruption of the SR-A1 signal transduction through molecular inhibition by Lyn kinase oligonucleotides not only blocks the activation of downstream TLR-9 pathway but also alters the downstream TLR-3 pathway. Oligonucleotides 101-117 toll like receptor 9 Homo sapiens 163-168 21978158-6 2011 In particular, Lyn kinase oligonucleotides resulted in decreased expression of TLR-9-induced tumor necrosis factor alpha (TNF-alpha) but strongly upregulated canonical TLR-3-induced interferon beta (IFN-beta) and non-canonical TLR-3-induced NF-kappaB-dependent p35 (35kDa) subunit of interleukin 12 (IL-12p35) gene transcription. Oligonucleotides 26-42 toll like receptor 9 Homo sapiens 79-84 22092186-3 2011 When incubated with oligonucleotides containing CpGs, immune cells are stimulated through TLR9 to produce and secrete cytokine mediators such as interleukin-6 (IL-6) and interleukin-12p70 (IL-12p70), a process associated with the initiation of an immune response. Oligonucleotides 20-36 toll like receptor 9 Homo sapiens 90-94 21953639-6 2011 It is of note that inhibitory oligonucleotides (IN-ODNs) do not affect TLR9 cleavage but competitively prevent CpG-ligand binding to the C-terminal TLR9 fragment. Oligonucleotides 30-46 toll like receptor 9 Homo sapiens 148-152 21820332-3 2011 Parasite DNA, parasitized erythrocytes and oligonucleotides containing the AT-rich motif induce type I IFNs via a pathway that did not involve the previously described sensors TLR9, DAI, RNA polymerase-III or IFI16/p204. Oligonucleotides 43-59 toll like receptor 9 Homo sapiens 176-180 21778270-7 2011 The CpG oligonucleotide, a TLR9 ligand, stimulated the NF-kappaB activity in HCEn cells. Oligonucleotides 8-23 toll like receptor 9 Homo sapiens 27-31 21483736-1 2011 Toll-like receptor 9 (TLR9) activates the innate immune system in response to oligonucleotides rich in CpG whereas DNA lacking CpG could inhibit its activation. Oligonucleotides 78-94 toll like receptor 9 Homo sapiens 0-20 21093498-0 2011 Adjuvating the adjuvant: facilitated delivery of an immunomodulatory oligonucleotide to TLR9 by a cationic antimicrobial peptide in dendritic cells. Oligonucleotides 69-84 toll like receptor 9 Homo sapiens 88-92 20570863-7 2010 Normal B cells can be activated by specific unmethylated cytosine-phosphate-guanosine (CpG) DNA motifs through toll-like receptor 9, and we found that the synthetic CpG oligonucleotide 2006 (CpG) reduced the frequency of quiescent ALDH(+) MCL cells, induced terminal plasma cell differentiation, and limited tumor formation in vitro and in vivo. Oligonucleotides 169-184 toll like receptor 9 Homo sapiens 111-131 20381019-1 2010 Novel agonists of TLR9 with two 5"-ends and synthetic immune stimulatory motifs, referred to as immune modulatory oligonucleotides (IMOs) are potent agonists of TLR9. Oligonucleotides 114-130 toll like receptor 9 Homo sapiens 18-22 20456414-6 2010 DNA- or RNA-like synthetic inhibitory oligonucleotides (INH-ODN) have been developed that antagonize TLR-7- and/or TLR-9-induced activation in autoimmune B cells and in type I IFN-producing dendritic cells at low nanomolar concentrations. Oligonucleotides 38-54 toll like receptor 9 Homo sapiens 115-120 20381019-1 2010 Novel agonists of TLR9 with two 5"-ends and synthetic immune stimulatory motifs, referred to as immune modulatory oligonucleotides (IMOs) are potent agonists of TLR9. Oligonucleotides 114-130 toll like receptor 9 Homo sapiens 161-165 20490286-7 2010 In this review, we describe recent achievements in the development of oligonucleotide-(ODN)-based inhibitors of TLR9 and/or TLR7 signaling. Oligonucleotides 70-85 toll like receptor 9 Homo sapiens 112-116 19903791-3 2009 We previously found that a novel toll-like receptor 9 agonist, referred to as immune modulatory oligonucleotide (IMO) and currently under clinical investigation, acts through epidermal growth factor receptor (EGFR) and shows direct antiangiogenic effects by cooperating with anti-EGFR or anti-VEGF drugs, thus interfering with cancer cells and microenvironment. Oligonucleotides 96-111 toll like receptor 9 Homo sapiens 33-53 19319670-1 2009 Toll like receptor 9 (TLR9) was identified mainly in cells of the immune system, and CpG oligonucleotides (CpG ODN), which induces signaling through TLR9, are currently under investigation as adjuvants in clinical therapies against cancer. Oligonucleotides 89-105 toll like receptor 9 Homo sapiens 149-153 19864612-1 2009 Synthetic oligonucleotides containing CpG motifs have been shown to induce proliferation, differentiation, and cytokine production in B cells, macrophages, and dendritic cells through a TLR9-dependent mechanism. Oligonucleotides 10-26 toll like receptor 9 Homo sapiens 186-190 19623161-4 2009 To further enhance the efficacy of the hTERT vaccine, we evaluated the combination of hTERT vaccine and a novel TLR9 agonist, referred to as immunomodulatory oligonucleotide (IMO). Oligonucleotides 158-173 toll like receptor 9 Homo sapiens 112-116 19724876-7 2009 We found that ERalpha-mediated transcription via estrogen response element of human breast cancer cells line T47D was significantly suppressed when treated with 17beta-estradiol in combination with TLR9 agonist CpG oligonucleotides and this effect of CpG was dependent on TLR9. Oligonucleotides 215-231 toll like receptor 9 Homo sapiens 198-202 19724876-7 2009 We found that ERalpha-mediated transcription via estrogen response element of human breast cancer cells line T47D was significantly suppressed when treated with 17beta-estradiol in combination with TLR9 agonist CpG oligonucleotides and this effect of CpG was dependent on TLR9. Oligonucleotides 215-231 toll like receptor 9 Homo sapiens 272-276 19139565-7 2009 Stimulation of 1alpha25VitD3-induced IL-10-secreting Treg with TLR9 agonists, CpG oligonucleotides, resulted in decreased IL-10 and IFN-gamma synthesis and a concurrent loss of regulatory function, but, unexpectedly, increased IL-4 synthesis. Oligonucleotides 82-98 toll like receptor 9 Homo sapiens 63-67 19252531-1 2009 Toll-like receptor 9 (TLR9) is part of the innate immune system, which is activated by CpG oligonucleotides (ODNs) and produces potent Th1-type innate and adaptive immune responses. Oligonucleotides 91-107 toll like receptor 9 Homo sapiens 0-20 19252531-1 2009 Toll-like receptor 9 (TLR9) is part of the innate immune system, which is activated by CpG oligonucleotides (ODNs) and produces potent Th1-type innate and adaptive immune responses. Oligonucleotides 91-107 toll like receptor 9 Homo sapiens 22-26 19299739-5 2009 The telomere-derived TLR9 inhibitory oligonucleotide 5"-TTT AGG GTT AGG GTT AGG G-3", agents that block endosomal acidification such as chloroquine and bafilomycin A, and NF-kappaB inhibitors abrogated CpG DNA-induced signaling. Oligonucleotides 37-52 toll like receptor 9 Homo sapiens 21-25 17469139-9 2007 This was prevented by CCGG-rich short oligonucleotides, specific antagonists of CpG DNA, indicating that the DNA component of immune complexes was required for TLR-9 stimulation. Oligonucleotides 38-54 toll like receptor 9 Homo sapiens 160-165 18852281-9 2008 Taken together, the present results suggest that oligonucleotide-based agonists of TLR9 that form intermolecular duplexes induce potent immune responses in vivo. Oligonucleotides 49-64 toll like receptor 9 Homo sapiens 83-87 18922969-0 2008 Toll-like receptor 9 mediates CpG oligonucleotide-induced cellular invasion. Oligonucleotides 34-49 toll like receptor 9 Homo sapiens 0-20 18922969-2 2008 We showed previously that treatment with the TLR9-agonistic ODN M362 (a CpG sequence containing oligonucleotide) induces matrix metalloproteinase-13-mediated invasion in TLR9-expressing human cancer cell lines. Oligonucleotides 96-111 toll like receptor 9 Homo sapiens 45-49 18922969-2 2008 We showed previously that treatment with the TLR9-agonistic ODN M362 (a CpG sequence containing oligonucleotide) induces matrix metalloproteinase-13-mediated invasion in TLR9-expressing human cancer cell lines. Oligonucleotides 96-111 toll like receptor 9 Homo sapiens 170-174 18922969-11 2008 In conclusion, our results suggest that TLR9 expression is increased in breast cancer and CpG oligonucleotide-induced cellular invasion is mediated via TLR9 and TRAF6, independent of MyD88. Oligonucleotides 94-109 toll like receptor 9 Homo sapiens 40-44 18922969-11 2008 In conclusion, our results suggest that TLR9 expression is increased in breast cancer and CpG oligonucleotide-induced cellular invasion is mediated via TLR9 and TRAF6, independent of MyD88. Oligonucleotides 94-109 toll like receptor 9 Homo sapiens 152-156 18606688-3 2008 In silico wide analysis associated with in vitro screening of synthetic oligonucleotides demonstrates that the retrotransposon VIPER elements and mucin-like glycoprotein (TcMUC) genes in the T. cruzi genome are highly enriched for CpG motifs that are immunostimulatory for mouse and human TLR9, respectively. Oligonucleotides 72-88 toll like receptor 9 Homo sapiens 289-293 18200500-4 2008 In a previous work, we observed an impaired IFN-alpha production in enriched cord blood pDC following a TLR9 stimulation using CpG oligonucleotides. Oligonucleotides 131-147 toll like receptor 9 Homo sapiens 104-108 17636117-3 2007 We recently discovered that a synthetic agonist of TLR9, immune modulatory oligonucleotide (IMO), acts by impairing epidermal growth factor receptor (EGFR) signaling and potently synergizes with anti-EGFR antibody cetuximab in GEO human colon cancer xenografts, whereas it is ineffective in VEGF-overexpressing cetuximab-resistant GEO cetuximab-resistant (GEO-CR) tumors. Oligonucleotides 75-90 toll like receptor 9 Homo sapiens 51-55 17988082-5 2007 The results presented here provide insight into which specific chemical modifications at C or G of the CpG motif are recognized by TLR9 and the ability to modulate immune responses substituting natural C or G in immune modulatory oligonucleotides. Oligonucleotides 230-246 toll like receptor 9 Homo sapiens 131-135 17917415-5 2007 Single-stranded oligonucleotides containing CpG dinucleotides (CpG DNA) are recognized by Toll-like receptor-9 on antigen-presenting cells such as macrophages to stimulate Th-1-type immune responses. Oligonucleotides 16-32 toll like receptor 9 Homo sapiens 90-110 17273997-3 2007 TLR-3 and TLR-4 induce IFN-beta by activating IRF-3; TLR-9 induces IFN-alpha and IFN-beta through IRF-7, at least when engaged by type A CpG oligonucleotides (CpG-A) in plasmacytoid DC (pDC). Oligonucleotides 141-157 toll like receptor 9 Homo sapiens 53-58 17363956-0 2007 Toll-like receptor 9-independent suppression of skin inflammation by oligonucleotides. Oligonucleotides 69-85 toll like receptor 9 Homo sapiens 0-20 17273997-4 2007 In this issue of the European Journal of Immunology, it is demonstrated that TLR-9 induces IFN-beta when engaged by type B CpG oligonucleotides (CpG-B) in myeloid DC and macrophages. Oligonucleotides 127-143 toll like receptor 9 Homo sapiens 77-82 15762869-4 2005 Attempts to neutralize this activity either by blocking the acidification of the endosomal compartment with chloroquine and related compounds, or by preventing the interaction between the CpG-DNA sequences and TLR9 using inhibitory oligonucleotides could be a promising therapeutic option for lupus. Oligonucleotides 232-248 toll like receptor 9 Homo sapiens 210-214 17108047-6 2007 A role for Toll-like receptor 9 (TLR9) recognition of Ad was supported by the requirement for viral DNA and efficient endosomal acidification and by the ability of a TLR9-inhibitory oligonucleotide to attenuate IFN-alpha induction. Oligonucleotides 182-197 toll like receptor 9 Homo sapiens 11-31 17108047-6 2007 A role for Toll-like receptor 9 (TLR9) recognition of Ad was supported by the requirement for viral DNA and efficient endosomal acidification and by the ability of a TLR9-inhibitory oligonucleotide to attenuate IFN-alpha induction. Oligonucleotides 182-197 toll like receptor 9 Homo sapiens 33-37 17108047-6 2007 A role for Toll-like receptor 9 (TLR9) recognition of Ad was supported by the requirement for viral DNA and efficient endosomal acidification and by the ability of a TLR9-inhibitory oligonucleotide to attenuate IFN-alpha induction. Oligonucleotides 182-197 toll like receptor 9 Homo sapiens 166-170 16952134-2 2006 We have investigated the structure-activity relationship (SAR) of base-modified CpG oligonucleotides with TLR9 by measuring TLR9 activation by 20-mer oligonucleotides having just a single human recognition motif (5"-GTCGTT-3") in functional cell-based TLR9 assays. Oligonucleotides 84-100 toll like receptor 9 Homo sapiens 106-110 16818518-0 2006 Chemotherapy and chemosensitization of non-small cell lung cancer with a novel immunomodulatory oligonucleotide targeting Toll-like receptor 9. Oligonucleotides 96-111 toll like receptor 9 Homo sapiens 122-142 16818518-6 2006 We also examined NSCLC cells for expression of Toll-like receptor 9 (TLR9), the receptor for the immunomodulatory oligonucleotide. Oligonucleotides 114-129 toll like receptor 9 Homo sapiens 47-67 16818518-6 2006 We also examined NSCLC cells for expression of Toll-like receptor 9 (TLR9), the receptor for the immunomodulatory oligonucleotide. Oligonucleotides 114-129 toll like receptor 9 Homo sapiens 69-73 16818518-8 2006 The immunomodulatory oligonucleotide has potent antitumor effects as monotherapy and in combination with conventional chemotherapeutic agents, and may act directly on NSCLC cells via TLR9. Oligonucleotides 21-36 toll like receptor 9 Homo sapiens 183-187 16610762-2 2006 These mechanisms include RNase H-mediated antisense, steric block antisense and small interfering RNA targeting viral RNAs, but also other mechanisms, including blockage of virus uptake by cells and the stimulation of a Toll-like receptor-9-dependent immune response by CpG oligonucleotides. Oligonucleotides 274-290 toll like receptor 9 Homo sapiens 220-240 16567503-3 2006 We demonstrate that CpG oligonucleotides activate a TLR9-independent pathway initiated by two Src family kinases, Hck and Lyn, which trigger a tyrosine phosphorylation-mediated signaling cascade. Oligonucleotides 24-40 toll like receptor 9 Homo sapiens 52-56 16922592-1 2006 CpG 7909 [PF-3512676] is an immunomodulating synthetic oligonucleotide designed to specifically agonise the Toll-like receptor 9 (TLR9). Oligonucleotides 55-70 toll like receptor 9 Homo sapiens 108-128 16922592-1 2006 CpG 7909 [PF-3512676] is an immunomodulating synthetic oligonucleotide designed to specifically agonise the Toll-like receptor 9 (TLR9). Oligonucleotides 55-70 toll like receptor 9 Homo sapiens 130-134 16922592-28 2006 6,653,292, which protects the use of TLR9-containing oligonucleotides to treat or prevent cancer or to enhance multimodal cancer treatment regimens. Oligonucleotides 53-69 toll like receptor 9 Homo sapiens 37-41 17226959-4 2007 Particles displaying CpG oligonucleotide ligands for Toll-like receptor 9 were synthesized. Oligonucleotides 25-40 toll like receptor 9 Homo sapiens 53-73 16864658-2 2006 Three classes of CpG oligonucleotide ligands for Toll-like receptor (TLR)9 can be distinguished by different sequence motifs and different abilities to stimulate IFN-alpha production and maturation of PDCs. Oligonucleotides 21-36 toll like receptor 9 Homo sapiens 69-74 16849519-3 2006 Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Oligonucleotides 79-95 toll like receptor 9 Homo sapiens 15-19 16849519-3 2006 Stimulation of TLR9-expressing breast cancer cells with the TLR9 agonistic CpG oligonucleotides (1-10 mumol/L) dramatically increased their in vitro invasion in both Matrigel assays and three-dimensional collagen cultures. Oligonucleotides 79-95 toll like receptor 9 Homo sapiens 60-64 16849519-5 2006 This effect was not, however, dependent on the CpG content of the TLR9 ligands because the non-CpG oligonucleotides induced invasion of TLR9-expressing cells. Oligonucleotides 99-115 toll like receptor 9 Homo sapiens 136-140 16849519-9 2006 Furthermore, CpG oligonucleotide treatment decreased tissue inhibitor of metalloproteinase-3 expression and increased levels of active MMP-13 in TLR9-expressing but not TLR9(-) breast cancer cells without affecting MMP-8. Oligonucleotides 17-32 toll like receptor 9 Homo sapiens 145-149 15860583-0 2005 Immunomodulatory oligonucleotides containing a cytosine-phosphate-2"-deoxy-7-deazaguanosine motif as potent toll-like receptor 9 agonists. Oligonucleotides 17-33 toll like receptor 9 Homo sapiens 108-128 15634876-0 2005 Cutting edge: species-specific TLR9-mediated recognition of CpG and non-CpG phosphorothioate-modified oligonucleotides. Oligonucleotides 102-118 toll like receptor 9 Homo sapiens 31-35 15709004-6 2005 Since previous work showed that TLR9 ligands include bacterial DNA and certain oligonucleotides containing unmethylated CpG dinucleotides, we also examined the effect of baculoviral DNA on the induction of innate immunity. Oligonucleotides 79-95 toll like receptor 9 Homo sapiens 32-36 14688201-2 2004 Oligonucleotides containing CG dinucleotide (CpG-DNA) mimic the effect of unmethylated DNA and stimulate TLR9. Oligonucleotides 0-16 toll like receptor 9 Homo sapiens 105-109 15585868-6 2004 Furthermore, uninfected B cells and monocytes both increased cell surface TLR9, CD86, and HLA-DR in response to treatment with CpG-containing oligonucleotides, whereas cell surface TLR9 was down-modulated on infected dendritic cells by the addition of agonist oligonucleotide. Oligonucleotides 142-158 toll like receptor 9 Homo sapiens 74-78 15585868-6 2004 Furthermore, uninfected B cells and monocytes both increased cell surface TLR9, CD86, and HLA-DR in response to treatment with CpG-containing oligonucleotides, whereas cell surface TLR9 was down-modulated on infected dendritic cells by the addition of agonist oligonucleotide. Oligonucleotides 142-157 toll like receptor 9 Homo sapiens 74-78 15233737-3 2004 In addition, the conjugated oligonucleotides appear to have improved immunostimulatory abilities compared to free oligonucleotides, presumably due to enhanced activation of Toll-like receptor 9. Oligonucleotides 28-44 toll like receptor 9 Homo sapiens 173-193 15233737-3 2004 In addition, the conjugated oligonucleotides appear to have improved immunostimulatory abilities compared to free oligonucleotides, presumably due to enhanced activation of Toll-like receptor 9. Oligonucleotides 114-130 toll like receptor 9 Homo sapiens 173-193 15070685-3 2004 The recently identified class of CpG oligonucleotides (CpG-C) was used to activate both B cells and PDCs via Toll-like receptor 9 (TLR9). Oligonucleotides 37-53 toll like receptor 9 Homo sapiens 109-129 15070685-3 2004 The recently identified class of CpG oligonucleotides (CpG-C) was used to activate both B cells and PDCs via Toll-like receptor 9 (TLR9). Oligonucleotides 37-53 toll like receptor 9 Homo sapiens 131-135 14559840-5 2003 Functional activity of PDC was examined by using CpG motif containing oligonucleotides, a defined microbial stimulus for PDCs (recognized via toll-like receptor 9). Oligonucleotides 70-86 toll like receptor 9 Homo sapiens 142-162 14607920-0 2003 Antigenic epitopes fused to cationic peptide bound to oligonucleotides facilitate Toll-like receptor 9-dependent, but CD4+ T cell help-independent, priming of CD8+ T cells. Oligonucleotides 54-70 toll like receptor 9 Homo sapiens 82-102 15588423-2 2004 The activation of TLR9 by microbial DNA or synthetic oligonucleotides based on these motifs leads to the induction of innate immune responses. Oligonucleotides 53-69 toll like receptor 9 Homo sapiens 18-22 12946990-1 2003 Immunostimulatory sequences (ISS) are short oligonucleotides containing unmethylated cytosine-phosphate-guanine (CpG) dinucleotides that stimulate innate immune responses through Toll-like receptor-9 on B cells and plasmacytoid dendritic cell (PDC) precursors. Oligonucleotides 44-60 toll like receptor 9 Homo sapiens 179-199 12689944-7 2003 Interestingly, a CpG oligonucleotide, a TLR9 agonist, also stimulated TLR9 expression in B cells. Oligonucleotides 21-36 toll like receptor 9 Homo sapiens 40-44 12689944-7 2003 Interestingly, a CpG oligonucleotide, a TLR9 agonist, also stimulated TLR9 expression in B cells. Oligonucleotides 21-36 toll like receptor 9 Homo sapiens 70-74 12669456-3 2003 Synthetic oligonucleotides (ODNs) containing these CpG motifs are able to activate both innate and acquired immune responses through a signaling pathway involving Toll-like receptor 9 (TLR9). Oligonucleotides 10-26 toll like receptor 9 Homo sapiens 163-183 12669456-3 2003 Synthetic oligonucleotides (ODNs) containing these CpG motifs are able to activate both innate and acquired immune responses through a signaling pathway involving Toll-like receptor 9 (TLR9). Oligonucleotides 10-26 toll like receptor 9 Homo sapiens 185-189 24995383-0 2014 Oligonucleotides designed to inhibit TLR9 block Herpes simplex virus type 1 infection at multiple steps. Oligonucleotides 0-16 toll like receptor 9 Homo sapiens 37-41 24995383-4 2014 We demonstrate a significant effect on HSV-1 replication in ARPE-19 and Vero cells when oligonucleotides designed to inhibit TLR9 are added 2h prior to infection. Oligonucleotides 88-104 toll like receptor 9 Homo sapiens 125-129 24995383-6 2014 TLR9 inhibitory oligonucleotides prevented expression of essential immediate early herpes gene products as determined by immunofluorescence microscopy and Western blotting. Oligonucleotides 16-32 toll like receptor 9 Homo sapiens 0-4 24995383-7 2014 TLR9 oligonucleotides also interfered with viral attachment and entry. Oligonucleotides 5-21 toll like receptor 9 Homo sapiens 0-4 24995383-8 2014 A TLR9 inhibitory oligonucleotide containing five adjacent guanosine residues (G-ODN) exhibited virucidal activity and inhibited HSV-1 replication when added post-infection. Oligonucleotides 18-33 toll like receptor 9 Homo sapiens 2-6 24995383-9 2014 The antiviral effect of the TLR9 inhibitory oligonucleotides did not depend on the presence of TLR9 protein, suggesting a mechanism of inhibition that is not TLR9 specific. Oligonucleotides 44-60 toll like receptor 9 Homo sapiens 28-32 24995383-10 2014 TLR9 inhibitory oligonucleotides also reduced NFkappaB activity in nuclear extracts. Oligonucleotides 16-32 toll like receptor 9 Homo sapiens 0-4 33783302-1 2021 INTRODUCTION: HEPLISAV-B is a hepatitis B vaccine composed of rHBsAg mixed with a synthetic oligonucleotide containing CpG motifs that stimulate innate immunity through TLR9. Oligonucleotides 92-107 toll like receptor 9 Homo sapiens 169-173 32827132-1 2021 CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 110-130 32827132-1 2021 CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides specifically designed to stimulate Toll-like receptor 9. Oligonucleotides 58-74 toll like receptor 9 Homo sapiens 110-130 31630153-1 2020 BACKGROUND AND AIMS: The topically applied Toll-like receptor 9 [TLR9] agonist cobitolimod is a first-in-class DNA-based oligonucleotide with demonstrated therapeutic efficacy in clinical trials with ulcerative colitis [UC] patients. Oligonucleotides 121-136 toll like receptor 9 Homo sapiens 43-63 33031757-1 2020 BACKGROUND: Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has shown clinical efficacy in patients with moderate-to-severe ulcerative colitis. Oligonucleotides 63-78 toll like receptor 9 Homo sapiens 94-114 33031757-1 2020 BACKGROUND: Cobitolimod is a topically administered, DNA-based oligonucleotide that activates Toll-like receptor 9 (TLR9), and previous research has shown clinical efficacy in patients with moderate-to-severe ulcerative colitis. Oligonucleotides 63-78 toll like receptor 9 Homo sapiens 116-120 31630153-1 2020 BACKGROUND AND AIMS: The topically applied Toll-like receptor 9 [TLR9] agonist cobitolimod is a first-in-class DNA-based oligonucleotide with demonstrated therapeutic efficacy in clinical trials with ulcerative colitis [UC] patients. Oligonucleotides 121-136 toll like receptor 9 Homo sapiens 65-69 31335975-1 2019 Bacterial DNA contains CpG oligonucleotide (ODN) motifs to trigger innate immune responses through the endosomal receptor Toll-like receptor 9 (TLR9). Oligonucleotides 27-42 toll like receptor 9 Homo sapiens 144-148 31805184-3 2020 Here, we describe a myeloid cell-selective NF-kappaB inhibitor using an miR-146a mimic oligonucleotide conjugated to a scavenger receptor/Toll-like receptor 9 agonist (C-miR146a). Oligonucleotides 87-102 toll like receptor 9 Homo sapiens 138-158 31470365-5 2020 IFNalpha in response to TLR9 activation, by CpG oligonucleotides, is tuned within a window of Ca2+ concentration, through a bimodal regulatory switch, by differential engagement of Ca2+/calmodulin-dependent protein kinase II (CAMKII) and calcineurin phosphatase (CALN). Oligonucleotides 48-64 toll like receptor 9 Homo sapiens 24-28 29526082-2 2018 CpG is an oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9) activation. Oligonucleotides 10-25 toll like receptor 9 Homo sapiens 70-90 30337279-3 2018 EXPERIMENTAL DESIGN: We developed and validated a conjugate of the STAT3 antisense oligonucleotide (ASO) tethered to immunostimulatory TLR9 agonist (CpG oligonucleotide) to improve targeting of human and mouse prostate cancer and myeloid immune cells, such as myeloid-derived suppressor cells (MDSC). Oligonucleotides 83-98 toll like receptor 9 Homo sapiens 135-139 30337279-3 2018 EXPERIMENTAL DESIGN: We developed and validated a conjugate of the STAT3 antisense oligonucleotide (ASO) tethered to immunostimulatory TLR9 agonist (CpG oligonucleotide) to improve targeting of human and mouse prostate cancer and myeloid immune cells, such as myeloid-derived suppressor cells (MDSC). Oligonucleotides 153-168 toll like receptor 9 Homo sapiens 135-139 31068803-12 2019 Cobitolimod is a single strand oligonucleotide, which mimics bacterial DNA as its CpG dinucleotide sequences can be recognized by the Toll-like receptor 9 on different immune cells thereby causing induction of different cytokines, for example IL10 and IFNalpha. Oligonucleotides 31-46 toll like receptor 9 Homo sapiens 134-154 29526082-2 2018 CpG is an oligonucleotide that activates the innate immune system via Toll-like receptor 9 (TLR9) activation. Oligonucleotides 10-25 toll like receptor 9 Homo sapiens 92-96 25855902-11 2015 Inhibition of Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RNA attenuated human coronary artery endothelial cell responses to CpG DNA. Oligonucleotides 91-106 toll like receptor 9 Homo sapiens 14-34 28214929-5 2017 Conjugation of a STAT3siRNA or decoy STAT3 inhibitors to synthetic Toll-like Receptor 9 (TLR9) agonists, CpG oligonucleotides, allowed for selective delivery into TLR9-positive cells. Oligonucleotides 109-125 toll like receptor 9 Homo sapiens 67-87 28214929-5 2017 Conjugation of a STAT3siRNA or decoy STAT3 inhibitors to synthetic Toll-like Receptor 9 (TLR9) agonists, CpG oligonucleotides, allowed for selective delivery into TLR9-positive cells. Oligonucleotides 109-125 toll like receptor 9 Homo sapiens 89-93 28214929-5 2017 Conjugation of a STAT3siRNA or decoy STAT3 inhibitors to synthetic Toll-like Receptor 9 (TLR9) agonists, CpG oligonucleotides, allowed for selective delivery into TLR9-positive cells. Oligonucleotides 109-125 toll like receptor 9 Homo sapiens 163-167 28214929-10 2017 In this article, we review the preclinical data on CpG-STAT3 inhibitors and discuss perspectives of using TLR9-targeted delivery of oligonucleotide therapeutics for the generation of novel, more effective and safer cancer immunotherapies. Oligonucleotides 132-147 toll like receptor 9 Homo sapiens 106-110 27718183-2 2017 Oligonucleotides containing unmethylated CpG sequences represent one alternative as they are potent stimulators of the vertebrate innate immune system through activation of Toll-like receptor-9. Oligonucleotides 0-16 toll like receptor 9 Homo sapiens 173-193 29717061-4 2018 We showed that after the stimulation of TLR9 by CpG oligonucleotides, the autophagy protein LC3 and the kinase IKKalpha were recruited to endosomes that contained TLR9. Oligonucleotides 52-68 toll like receptor 9 Homo sapiens 40-44 29717061-4 2018 We showed that after the stimulation of TLR9 by CpG oligonucleotides, the autophagy protein LC3 and the kinase IKKalpha were recruited to endosomes that contained TLR9. Oligonucleotides 52-68 toll like receptor 9 Homo sapiens 163-167 29439958-1 2018 We previously reported that Toll-like receptor 9 (TLR9)-CpG oligonucleotides could inhibit the establishment of hepatitis B virus (HBV) infections in hepatocytes. Oligonucleotides 60-76 toll like receptor 9 Homo sapiens 50-54 29439958-9 2018 To conclude, our data suggest that synthetic TLR9-CpG oligonucleotides can strongly inhibit HBV entry by "coating" HBV virions and thereby preventing their interaction with cellular receptor. Oligonucleotides 54-70 toll like receptor 9 Homo sapiens 45-49 29423660-0 2018 Targeting Suppressive Oligonucleotide to Lymph Nodes Inhibits Toll-like Receptor-9-Mediated Activation of Adaptive Immunity. Oligonucleotides 22-37 toll like receptor 9 Homo sapiens 62-82 28500073-4 2017 TLR9 accumulates on the cell surface, where it recognizes CpG oligonucleotide 2006. Oligonucleotides 62-77 toll like receptor 9 Homo sapiens 0-4 27572942-3 2016 The oral synthetic oligonucleotide toll-like receptor-9 modulator has demonstrated anti-inflammatory properties in colitis murine models and a satisfactory safety profile in humans. Oligonucleotides 19-34 toll like receptor 9 Homo sapiens 35-55 27579996-2 2016 We hypothesized that codelivery of a regulatory ligand of TLR9, GpG oligonucleotide, along with myelin-the "self" molecule attacked in MS-might restrain the pro-inflammatory signaling typically present during myelin presentation, redirecting T cell differentiation away from inflammatory populations and toward tolerogenic phenotypes such as regulatory T cells. Oligonucleotides 68-83 toll like receptor 9 Homo sapiens 58-62 27579996-5 2016 In vitro, iPEMs assembled from myelin and GpG oligonucleotide, but not myelin and a control oligonucleotide, restrain TLR9 signaling, reduce dendritic cell activation, and polarize myelin-specific T cells toward tolerogenic phenotype and function. Oligonucleotides 46-61 toll like receptor 9 Homo sapiens 118-122 26152778-2 2015 Herein, we demonstrate that interferon (IFN)-alpha, either endogenously produced after exposure of cells to toll-like receptor-9-activating CpG oligonucleotides or provided as recombinant cytokine, weakens activation of the anti-bacterial interleukin (IL)-1/IL-22 axis in human peripheral blood mononuclear cells exposed to viable B. burgdorferi. Oligonucleotides 144-160 toll like receptor 9 Homo sapiens 108-128 26034339-3 2015 These oligonucleotides enable the optical control of TLR9 function and thereby provide light-activation of an immune response. Oligonucleotides 6-22 toll like receptor 9 Homo sapiens 53-57 25855902-11 2015 Inhibition of Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RNA attenuated human coronary artery endothelial cell responses to CpG DNA. Oligonucleotides 91-106 toll like receptor 9 Homo sapiens 59-79 25855902-11 2015 Inhibition of Toll-like receptor 9 with a telomere-derived Toll-like receptor 9 inhibitory oligonucleotide or transient Toll-like receptor 9 knockdown with small interfering RNA attenuated human coronary artery endothelial cell responses to CpG DNA. Oligonucleotides 91-106 toll like receptor 9 Homo sapiens 59-79 26451303-1 2015 The immunostimulatory ability of synthetic oligonucleotides containing CpG motifs (CpG-ODN), agonists of Toll-like receptor 9 (TLR9), can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate local activation of innate immunity; however, particularly in the lung, tumor-associated immunosuppression can subvert such antitumor innate immune responses. Oligonucleotides 43-59 toll like receptor 9 Homo sapiens 105-125 26451303-1 2015 The immunostimulatory ability of synthetic oligonucleotides containing CpG motifs (CpG-ODN), agonists of Toll-like receptor 9 (TLR9), can be harnessed to promote antitumor immunity by their application at the tumor site to stimulate local activation of innate immunity; however, particularly in the lung, tumor-associated immunosuppression can subvert such antitumor innate immune responses. Oligonucleotides 43-59 toll like receptor 9 Homo sapiens 127-131 25627002-1 2015 PURPOSE: The immune modulatory oligonucleotide IMO-2055 (EMD 1201081) is a phosphorothioate oligodeoxynucleotide agonist of Toll-like receptor 9. Oligonucleotides 31-46 toll like receptor 9 Homo sapiens 124-144 24647486-4 2014 We further characterized the direct effects of TLR9 agonist CpG oligonucleotides (CpG ODN) and inhibitor chloroquine (CQ), on the proliferation and invasion of EC cells in vitro. Oligonucleotides 64-80 toll like receptor 9 Homo sapiens 47-51 25695778-0 2015 Guanine-modified inhibitory oligonucleotides efficiently impair TLR7- and TLR9-mediated immune responses of human immune cells. Oligonucleotides 28-44 toll like receptor 9 Homo sapiens 74-78 25441838-4 2014 TLR-9, localized in endosomal compartment, specifically recognizes unmethylated oligonucleotide sequences containing CpG motifs which are particularly abundant in microbial genome, including HIV-1 DNA. Oligonucleotides 80-95 toll like receptor 9 Homo sapiens 0-5 28548068-5 2014 Several synthetic CpG oligonucleotides (ODNs) have been developed as TLR-9 agonists with the aim of enhancing cancer immune surveillance. Oligonucleotides 22-38 toll like receptor 9 Homo sapiens 69-74 24975812-1 2014 Synthetic oligonucleotides (ODN) that express unmethylated "CpG motifs" trigger cells that express Toll-like receptor 9. Oligonucleotides 10-26 toll like receptor 9 Homo sapiens 99-119 24308579-1 2014 CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 108-128 24308579-1 2014 CpG Oligonucleotides (ODN) are immunomodulatory synthetic oligonucleotides designed to specifically agonize Toll-like receptor 9. Oligonucleotides 58-74 toll like receptor 9 Homo sapiens 108-128 23864774-2 2013 Amongst TLRs, TLR9 can be activated by such bacterial or viral DNA fragments, immunoglobulin-DNA complexes or synthetic oligonucleotides, which all contain unmethylated cytosine-guanine nucleotide sequences (CpGs). Oligonucleotides 120-136 toll like receptor 9 Homo sapiens 14-18 24466313-7 2014 NF-kappaB inhibitors and the telomere-derived TLR9 inhibitory oligonucleotide 5"-TTT AGG GTT AGG GTT AGG G-3" markedly reduced Mcl-1 protein levels and subsequently abrogated suppression of apoptosis by CpG DNA. Oligonucleotides 62-77 toll like receptor 9 Homo sapiens 46-50 23686399-6 2013 TLR9 ligands, oligo-nucleotides containing unmethylated CpG motifs, indeed bind to surface TLR9 and binding was strongly observed at the cell surface of human cells expressing surface TLR9 and at the surface of WT but not TLR9-deficient mouse PMNs. Oligonucleotides 14-31 toll like receptor 9 Homo sapiens 0-4 23686399-6 2013 TLR9 ligands, oligo-nucleotides containing unmethylated CpG motifs, indeed bind to surface TLR9 and binding was strongly observed at the cell surface of human cells expressing surface TLR9 and at the surface of WT but not TLR9-deficient mouse PMNs. Oligonucleotides 14-31 toll like receptor 9 Homo sapiens 91-95 23686399-6 2013 TLR9 ligands, oligo-nucleotides containing unmethylated CpG motifs, indeed bind to surface TLR9 and binding was strongly observed at the cell surface of human cells expressing surface TLR9 and at the surface of WT but not TLR9-deficient mouse PMNs. Oligonucleotides 14-31 toll like receptor 9 Homo sapiens 91-95 23686399-6 2013 TLR9 ligands, oligo-nucleotides containing unmethylated CpG motifs, indeed bind to surface TLR9 and binding was strongly observed at the cell surface of human cells expressing surface TLR9 and at the surface of WT but not TLR9-deficient mouse PMNs. Oligonucleotides 14-31 toll like receptor 9 Homo sapiens 91-95 23686399-7 2013 Finally, CpG oligonucleotides cross-linked onto a solid phase and having no access to intracellular TLR9 are able to trigger cell surface TLR9 and induce neutrophil activation, even when endosomal acidification is inhibited. Oligonucleotides 13-29 toll like receptor 9 Homo sapiens 138-142 24619691-2 2014 CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 155-175 24619691-2 2014 CpG oligonucleotides (CpG ODN) activate and support the maturation of immune cells, including plasmacytoid dendritic cells and B lymphocytes, that express Toll-like receptor 9 (TLR9) and are capable of presenting tumor antigens to T cells. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 177-181 23755833-3 2013 In this study, we employ polymer blend particles to present the synthetic ligand, CpG oligonucleotides (CpG ODNs), to TLR9. Oligonucleotides 86-102 toll like receptor 9 Homo sapiens 118-122 23616277-1 2013 Synthetic oligonucleotides (ODN) expressing CpG motifs mimic the ability of bacterial DNA to trigger the innate immune system via TLR9. Oligonucleotides 10-26 toll like receptor 9 Homo sapiens 130-134 23571736-2 2013 The Toll-like receptor 9 agonist immune modulatory oligonucleotide (IMO) exhibits direct antitumour and antiangiogenic activity and cooperates with both epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) inhibitors. Oligonucleotides 51-66 toll like receptor 9 Homo sapiens 4-24 23140401-1 2012 INTRODUCTION: Progranulin (PGRN) is the precursor of granulin (GRN), a soluble cofactor for toll-like receptor 9 (TLR9) signaling evoked by oligonucleotide (CpG)-DNA. Oligonucleotides 140-155 toll like receptor 9 Homo sapiens 114-118 23396449-1 2013 Oligonucleotides containing an immune-stimulatory motif and an immune-regulatory motif act as antagonists of Toll-like receptor (TLR)7 and TLR9. Oligonucleotides 0-16 toll like receptor 9 Homo sapiens 139-143 22941279-1 2012 CpG oligonucleotides (CpG ODNs) interact with Toll-like receptor 9 (TLR9), which results in the induction of immunostimulatory cytokines. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 46-66 22941279-1 2012 CpG oligonucleotides (CpG ODNs) interact with Toll-like receptor 9 (TLR9), which results in the induction of immunostimulatory cytokines. Oligonucleotides 4-20 toll like receptor 9 Homo sapiens 68-72